Willis Chandler, AmerisourceBergen’s recently named President of Biopharma Services, Strategic Global Sourcing and Commercial Solutions, talks about the new investments AB is making to build out its capabilities and its new cell and gene therapy service line.
Private-equity-funded conglomerate will offer life sciences commercialization services
Configuration-driven SaaS, powered by modern data management technology, can enable orphan drug manufacturers to form effective commercial strategies
Maria Whitman, global head of ZS’s pharmaceutical and biotech practice, talks about the upheaval of the pharma business model and what it means for sales reps; the current skills gap in the marketplace; and how mega-mergers could soon be back on the agenda
Leveraging the value healthcare professionals place on scientific content
Catherine Humphries sheds light on three key market access challenges within the ophthalmology biosimilars space.
By 2024 oncology therapeutic sales will hit $250 billion worldwide, and there will be more than 22 million cancer survivors. But commercializing how these critical therapies come to market to help patients hasn’t changed much in the past 20 years. The industry must do more, write Anne Marie Robertson and Ellen Cappellino
Leaders from Janssen, Novartis Gene Therapies, Pierre Fabre, and the German cancer app start-up Mika discuss how they are leveraging data in innovative ways to advance their engagement with the scientific community and their overall commercial operations
What does digital innovation actually mean and how is it changing the way that pharma is interacting with HCPs and patients?
An interview with Matthew Aubin of Sonexus™ Access & Patient Support.
Sandra Anderson outlines what manufacturers need to know about the regulatory environment and commercialization solutions for the Canadian market.
The benefits of establishing an in-depth go-to-market commercialization strategy for a new CGT in the beginning of clinical trials
Taking cues from launches so far in oncology and rheumatology, three important considerations for biosimilar marketability are outlined
Focusing on key groups will drive the greatest impact in health outcomes
The biggest areas of adjustment in patient support brought on by changes in consumer and physician behavior
AI-driven strategies for pharma brand marketing teams to help bridge the gap from data intelligence to execution
How to best plan out and implement a marketing data hub as a key tool to harnessing today’s omnichannel transformation in pharma
Outlining the key digital trends accelerated by the transformed healthcare landscape in 2021—and their impact on pharma commercialization strategies going forward
How the development of more quantitative and qualitative data around the patient can drive better-informed care decisions—and help avoid potential overstock scenarios that can deplete earnings
How pharma’s retooling of its promotional efforts in the post-pandemic era impacts sizing and targeting, two crucial foundational pieces to successful commercialization
Arthrex to receive US rights to distribute and commercialize Celularity’s placental-derived biomaterial products for orthopedics and sports medicine
A conversation with Vin Colicchio, vice president, supply chain and external manufacturing, Dr. Reddy’s Laboratories
A well-oiled, data-driven hub program is critical for stakeholders in supporting patients—and clearing a successful path for specialty therapies
A conversation with Cathy Traz, global advocacy head at Bristol Myers Squibb
Covid-19 reveals how important field reps will be to driving digital adoption
